CATEGORY
New possibilities that change what we can diagnose, treat, prevent or understand in human health.
A UK program combining GLP-1 drugs with remote clinical checks reported mean weight reduction of 15.5% among women with six-month measurements. It demonstrates feasibility, not superiority over in-person care.
A pooled study of 1,038 patients links strong response to preoperative immunotherapy with favorable outcomes. The survival figure refers to a selected group, not every patient, and does not prove one regimen beats all others.
EAGLE reviews noncontrast chest CT scans for esophageal malignancy. In 17,446 prospectively screened patients it flagged 90, of whom 38 were confirmed positive. Only one additional cancer was diagnosed through the AI-triggered endoscopy pathway.
A sequencing method called uRARE-seq examined 683 urine samples and detected tumor signals with high sensitivity. It also suggested treatment-response biomarkers, but clinical utility needs prospective validation.
In randomized phase 3 TAISHAN-302, tambotatug pelitecan outperformed topotecan after platinum-based treatment. These are interim data from a Chinese trial, not proof of universal regulatory availability.
A model measuring blood-vessel patterns in retinal images achieved AUC 0.81 in independent-site testing. The new validation matters, but the small sample cannot establish screening benefit.
A single-arm phase 1 study followed eleven adolescents for 52 weeks after one BBM-H901 infusion. Factor IX activity rose and bleeding declined, but long-term safety and controlled efficacy remain unknown.
Biopsies from ten patients with severe enterocolitis after myeloma CAR-T treatment showed inflammation involving many tissue compartments. Two patients improved after a JAK inhibitor, an observation far from proof of treatment efficacy.
A Nature Medicine review of 3,967 open-access articles citing TRIPOD or TRIPOD+AI found code sharing in only 482, or 12.2%. Many accessible repositories also lacked features needed for reproducibility.
In the longest ESO-T01 follow-up, all four patients had initially responded; by 15 months only one remained in stringent complete response, while the other three progressed within five months.
